MAP2K7 and pneumocystosis: BRAF/MEK inhibitors have shown significant efficacy in treating recurrent PCP, but due to the small sample sizes and high heterogeneity of the studies, the results may not be fully applicable to all PCP patients, especially those with complex or comorbid conditions.